Wall Street expects a year-over-year increase in earnings on higher revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended September 2024. While this widely-known consensus ...

Sage guided to organic revenue growth of 9% or above for FY26, compared to consensus estimates of 8.7%. The guidance includes continued growth in margins, making FY26 consensus margins of 24% appear ...